Efficacy and safety of elranatamab monotherapy in patients with relapsed/refractory multiple myeloma: a post-hoc subgroup analysis from MagnetisMM-3 with modified eligibility criteria

被引：0

作者：

Raab, Marc ^{[1
]}

Manier, Salomon ^{[2
]}

Prince, H. Miles ^{[3
]}

Nooka, Ajay ^{[4
]}

Kaedbey, Rayan ^{[5
]}

Hillengass, Jens ^{[6
]}

Ishida, Tadao ^{[7
]}

Sullivan, Sharon ^{[8
]}

Conte, Umberto ^{[8
]}

Leip, Eric ^{[8
]}

Viqueira, Andrea ^{[9
]}

Raje, Noopur ^{[10
]}

机构：

[1] Univ Hosp Heidelberg, Dept Med Hematol Oncol & Rheumatol 5, Heidelberg, Germany

[2] Univ Lille, Ctr Hosp Univ Lille, Lille, France

[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[4] Emory Univ, Winship Canc Inst, Sch Med, Atlanta, GA USA

[5] McGill Univ, Montreal, PQ, Canada

[6] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[7] Japanese Red Cross Med Ctr, Tokyo, Japan

[8] Pfizer Inc, New York, NY USA

[9] Pfizer SLU, Madrid, Spain

[10] Massachusetts Gen Hosp, Boston, MA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-307

引用

页码：S207 / S208

页数：2

共 50 条

[41] Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study
Nooka, Ajay K.
Yee, Andrew J.
Huff, Carol Ann
Vogl, Dan T.
Gavriatopoulou, Maria
Chari, Ajai
Moreau, Philippe
Dingli, David
Cole, Craig E.
Lonial, Sagar
Dimopoulos, Meletios A.
Richter, Joshua R.
Vij, Ravi
Tuchman, Sascha A.
Raab, Marc S.
Biran, Noa
Siegel, David S.
Richardson, Paul G.
Liu, Jianjun
Joshi, Anita
Shah, Jatin
Shacham, Sharon
Kauffman, Michael G.
Jagannath, Sundar
BLOOD, 2019, 134
[42] Improvements in Renal Function with Selinexor in Relapsed/Refractory Multiple Myeloma: Post-hoc Analyses from the STORM Study
Vogl, Dan T.
Nooka, Ajay
Gavriatopoulou, Maria
Yee, Andrew
Huff, Carol
Moreau, Philippe
Dingli, David
Cole, Craig
Richardson, Paul G.
Dimopoulos, Meletios A.
Lonial, Sagar
Stewart, Keith
Chari, Ajai
Richter, Joshua
Biran, Noa
Siegel, David S.
Liu, Jianjun
Joshi, Anita
Shah, Jatin
Shacham, Sharon
Kauffman, Michael
Jagannath, Sundar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E118 - E119
[43] Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study
Kumar, Shaji
Vij, Ravi
Kaufman, Jonathan L.
Mikhael, Joseph
Facon, Thierry
Pegourie, Brigitte
Benboubker, Lofti
Gasparetto, Cristina
Amiot, Martine
Moreau, Philippe
Alzate, Stefanie
Ross, Jeremy
Dunbar, Martin
Xu, Tu
Agarwal, Suresh
Leverson, Joel
Maciag, Paulo
Verdugo, Maria
Touzeau, Cyrille
BLOOD, 2016, 128 (22)
[44] Efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis
Al-Badriyeh, Daoud
Shafei, Laila
Bashir, Shaima
Abushanab, Dina
Hamad, Anas
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 263 - 263
[45] Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis
Xiaohui Gao
Hui Zeng
Xiaoyan Zhao
Haibing Wu
Minchao Yan
Yuan Li
Gang Zhang
Fei Sun
BMC Cancer, 23
[46] EFFICACY AND SAFETY OF SELINEXOR FOR PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A META-ANALYSIS
Abushanab, D.
Mraiche, F.
Al-Badriyeh, D.
VALUE IN HEALTH, 2021, 24 : S22 - S22
[47] Efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis
Shafei, Laila
Bashir, Shaima
Chan, Esther W.
Abushanab, Dina
Hamad, Anas
Al-Badriyeh, Daoud
CURRENT PROBLEMS IN CANCER, 2024, 50
[48] Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1.
Jakubowiak, Andrzej J.
Bahlis, Nizar J.
Raje, Noopur S.
Costello, Caitlin
Dholaria, Bhagirathbhai R.
Solh, Melhem M.
Levy, Moshe Y.
Tomasson, Michael H.
Dube, Harman
Damore, Michael A.
Jiang, Sibo
Basu, Cynthia
Skoura, Athanasia
Chan, Edward Michael
Trudel, Suzanne
Chu, Michael P.
Gasparetto, Cristina J.
Dalovisio, Andrew Peter
Sebag, Michael
Lesokhin, Alexander M.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[49] Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis
Gao, Xiaohui
Zeng, Hui
Zhao, Xiaoyan
Wu, Haibing
Yan, Minchao
Li, Yuan
Zhang, Gang
Sun, Fei
BMC CANCER, 2023, 23 (01)
[50] Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11
Iida, Shinsuke
Sunami, Kazutaka
Mishima, Yuko
Fujii, Taku
Kato, Hitomi
Terao, Takumi
Matsuzawa, Yuki
Matsubara, Mari
Crossman, Timothy
Kremer, Brandon E.
Gupta, Ira
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 118 (05) : 596 - 608

← 1 2 3 4 5 →